The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials

BACKGROUND: The severe forms of asthma represent a major burden, because of severity of symptoms, costs and impact on everyday life. Recently, Mepolizumab (MEP) was approved and marketed for the treatment of hypereosinophilic severe asthma. This anti-IL-5 monoclonal antibody reduced exacerbation rat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:World Allergy Organ J
Päätekijät: Bagnasco, Diego, Milanese, Manlio, Rolla, Giovanni, Lombardi, Carlo, Bucca, Caterina, Heffler, Enrico, Canonica, Giorgio Walter, Passalacqua, Giovanni
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6282342/
https://ncbi.nlm.nih.gov/pubmed/30555618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40413-018-0210-7
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia